$50,000 Grant to Look For Predictive Gene(s) and New Epilepsy Causes in the Ion Channel

$50,000 Grant to Look For Predictive Gene(s) and New Epilepsy Causes in the Ion Channel

ICE is pleased to announce a grant of $50k awarded to Jeffrey Noebels, MD for saved samples from the FEBSTAT study conducted by Shlomo Shinnar, MD in infants and children with prolonged febrile seizures to look for a predictive gene or genes for the severe forms of febrile seizures leading to mesial hippocampal sclerosis, and hopefully preventative therapy.

read more

Board of Directors

Board of Directors

Michelle Welborn, PharmD President Lewisville, NC’ Peter Haeberli, JD Counsel, Merk Betsy English, MD Winston Salem NC ...

read more

ICE and DSF Fund the International Ion Channel Epilepsy Patient Registry

ICE and DSF Fund the International Ion Channel Epilepsy Patient Registry

ICE together with DSF Funds International Ion Channel Epilepsy Patient Registry, a joint effort between Miami Children’s Hospital and the University of Michigan

read more

Michelle Welborn, PharmD

Michelle Welborn, PharmD

Michelle Welborn holds a Doctor of Pharmacy degree from Campbell University School of Pharmacy. She serves as President and CEO of Bravo Pharmaceuticals, a small start-up biotech company that will provide novel pharmaceuticals and first to market generic products for rare diseases, including intractable childhood epilepsy.

read more

UPDATE 1-Lundbeck says clobazam effective in seizures

By John Acher COPENHAGEN, Dec 6 (Reuters) - Danish drugmaker H Lundbeck (LUN.CO) said it got positive results in a Phase 3 trial of its candidate drug clobazam in treating seizures associated with Lennox-Gastaut syndrome. Lennox-Gastaut syndrome (LGS) is is a rare and severe form of epilepsy and Lundbeck reiterated it expected to submit a new drug application for clobazam as an adjunctive treatment for LGS to the U.S. Food and Drug Administration by year-end.

read more